Regenera Activa in Turkey

Regenera Activa in Turkey: cellular micrografts and the level of evidence

Regenera Activa is the name dermatology literature gives to a technique of autologous cellular micrografts: the material used comes from the person being treated, and the method has been studied in male and female androgenetic alopecia. It belongs to the regenerative family of hair loss treatments, alongside platelet-rich plasma. In Istanbul, at our partner clinic, the surgeon weighs it against a transplant, meaning follicles taken from a donor area and moved to the surfaces that need covering. That surgical route has a course of its own, set out on the page about hair transplant in Turkey and in the hair transplant guide.

Zari published a retrospective cohort study on the technique in 2021, in Clinical, Cosmetic and Investigational Dermatology. It is the work that documents, as things stand, what cellular micrografts have produced, in which patients and over what follow-up. A second and wider publication places the whole regenerative family next to surgery. Those two readings frame the discussion the surgeon opens with you, and the quote then prices the procedure kept, free and with no obligation, within 24h.

The three measurements Zari reports

The study looks at autologous cellular micrografts, the Regenera technique, in androgenetic alopecia, in men and in women. The author records a mean rise in density of 4.5 to 7.12 hairs/cm² depending on the area, mean thickness up by +0.96 to +1.88 µm, and a favourable response in 66.4% of patients. All three are short-term results, from a single cohort (Zari, 2021).

The density range comes down to the area observed: within one series, the gap measured varies from one sector of the scalp to another. That spread translates straight into consultation. The surgeon at our partner clinic reads your photographs, then the scalp itself, to work out which areas still hold a density worth measuring and which call for a different conversation. A temple, a parting and a vertex each start from their own state, and it is that state which sets the scope proposed.

The two thickness figures cover mean hair calibre, in the same series and over the same short horizon. They put a number on the gain in diameter seen in that cohort. The 66.4% figure is something else: the share of patients the author classed as responders. It is a response rate at the level of the group studied, and the surgeon uses it as a marker when explaining what the technique has produced elsewhere, before turning to your own case.

The retrospective design and the short follow-up define what those three measurements are worth. A retrospective cohort brings together patients already treated, whose measurements were taken over the course of consultations and gathered afterwards; the protocol follows data that already exists rather than generating it. What the series establishes therefore holds for the group it describes, over the period actually observed, and that is the basis on which the surgeon uses it.

How often you attend, how many sessions there are and what the aftercare instructions say belong to the consultation: they are decided from the examination and written on the quote once the indication is kept. A scalp is judged on things the published averages do not carry, such as how long the loss has been going on, the way it has progressed over recent years and what the treatments already tried have given. Those come from your file and from the examination carried out in Istanbul.

A level of evidence below that of a transplant

Cruciani, Masiello, Pati and colleagues pulled together the literature on regenerative treatments for hair loss in 2023, centred on platelet-rich plasma. The evidence there is favourable while remaining heterogeneous and uneven in quality, and the authors place the level of evidence for cellular techniques below that of a transplant (Cruciani et al., 2023).

That hierarchy sets the order of the clinical discussion. Where the surgeon judges that follicles need moving, the transplant is still the route backed by the strongest body of work, and that is the one they propose. Cellular micrografts keep their place on a head of hair that is still full, within the field Zari observed, with the caution that level of evidence demands. This priority is stated to the patient from the first consultation, and it holds for every file.

In practice, that order shows in the way a consultation unfolds. The surgeon starts by looking at whether the donor reserve and the spread of the thinning point to a transplant, because that is the best documented question. They then look at what a cellular technique can support on the hair still there. This order protects your decision: reading the quote, you know which of the two routes rests on the wider body of work, and why the surgeon kept the one on the page.

The same hierarchy explains why the plan is written file by file. Within regenerative approaches, the published series do not all follow the same design, and an average drawn from an uneven body of work transfers badly to one particular scalp. So the surgeon at our partner clinic keeps what the examination allows, then puts it in writing. The Regenera Activa quote covers autologous cellular micrografts; platelet-rich plasma sits outside that package, and a transplant, where indicated, gets a line of its own.

Read in that order, Zari and Cruciani answer two different questions. The first puts numbers on what cellular micrografts produced, in the short term, in a cohort with androgenetic alopecia. The second maps regenerative treatments as a whole, favourable and uneven, and places these techniques next to a transplant. A file may call for one, for the other, for a transplant, or for doing nothing. The surgeon brings both readings together with the examination, and says out loud in consultation how the decision was reached.

Confirming androgenetic alopecia before pricing anything

Androgenetic alopecia is the diagnosis Zari’s series was built around, in men as much as in women. So it is the picture the surgeon sets out to establish first. Hair loss driven by hormones, by stress, by an illness or by a treatment under way can sit on top of that pattern or look very like it; the work-up is there to tell them apart, because the indication for cellular micrografts changes with the cause identified.

This step comes before any pricing. You send photographs of the scalp and the history the team asks for, from several angles and without filters, so the thinning can be placed properly. A view from above, a front view with the hairline clear and a shot of the back already give a usable density map; the team will say, during that first exchange, which shots are missing. The surgeon may ask for another photograph or for detail on a treatment already followed, and those refine the first opinion.

They then keep a plan: cellular micrografts, a transplant, both procedures one after the other, or nothing. The quote that follows, free and with no obligation, covers that precise scope, each procedure named. Doing nothing is said as plainly as the other three answers, and it reaches you before you commit to any travel.

The exchange happens in English from that first opinion onwards, and that has a practical bearing. An aftercare instruction, a doubt about a phase of thinning or the reading of a progress photo can then be put into words with no language sitting in between. Visible hair loss often weighs on how you feel about yourself, and that part of the file deserves a hearing in consultation; the technical decision, for its part, turns on the diagnosis and on the state of the hair still present.

The scope kept varies from one file to the next, even where two scalps look alike to the eye. How far the thinning has spread, the calibre of the hair still there, the treatments already followed and how stable the loss is all weigh in the decision. The first opinion says whether the figures Zari published mean anything in your situation, or whether your file calls for another examination first.

Two ways of treating thinning hair

A transplant restores density by moving follicles from a donor area to the areas that need cover. Autologous cellular micrografts work instead on the hair left in place, which assumes a head of hair still there, inside the field Zari observed. The surgeon points towards a transplant when the local reserve no longer allows any thickening; they open the discussion on Regenera Activa when hair remains and the picture fits androgenetic alopecia.

The two routes can follow one another where the surgeon recommends it. Each procedure then gets its own line on the quote, with its own indication and its own schedule, both settled after the file has been read. A transplant, once kept, follows an operative course of its own that Regenera Activa does not borrow; keeping the two schedules separate is what allows Zari’s study to be read for what it is, a series devoted to cellular micrografts.

The detail of the procedure and the aftercare instructions are set out in consultation, then written on the document you are given. Body Expert covers the stay, the language link and the year of contact; the medical content of the plan belongs to the surgeon at our partner clinic. What the publications leave open, starting with the schedule that applies to your scalp, is settled at that point, in the light of the examination.

How the stay is organised and what the quote covers

In 2024, Turkey was among the countries with the highest share of foreign patients for aesthetic procedures (ISAPS, 2025). That volume explains part of the set-up an English-speaking patient meets in Istanbul: teams used to patients arriving from abroad, a reception chain already in place, accommodation and journeys arranged in advance. What Regenera Activa itself can bring, though, is read in Zari’s study, then in the examination of your scalp.

At Body Expert, Regenera Activa takes place in Istanbul, at our partner clinic. The stay covers the 5-star hotel with nights and breakfast, the VIP transfers between airport, hotel and clinic, a dedicated English-speaking coordinator or interpreter, and 12 months of post-operative follow-up. Your flight stays at your own expense. English is the working language at every step, from the first message you send with your photos to the last check of the year, which lets aftercare instructions and medical questions travel without rough interpretation.

The quote, free and with no obligation, arrives within 24h. It lists the nights covered, the transfers, the dedicated coordinator or interpreter, the year of follow-up, and the cellular micrograft procedure kept. A transplant, where indicated, takes a separate line. You get that document before you fix your dates, and it becomes the shared reference, in English, for the adviser and the surgeon alike right through the project. A question asked three weeks later finds its answer in those lines, with no need to reconstruct an old conversation.

The path follows a steady sequence. You send your photographs and the relevant history; the surgeon gives a first opinion on whether cellular micrografts are worth considering and on how they differ from a transplant; the English-speaking adviser passes that opinion and the quote on to you. Once the dates are fixed, the arrival, the hotel and the transfers are set. In Istanbul, the examination goes back over the scalp itself, and the procedure follows the plan settled that way. The surgeon gives the aftercare instructions on the spot, the coordinator repeats them in English, and follow-up brings them back if a question returns once you are home.

That follow-up has a medical purpose, separate from the language link. A sharp photo, sent in time, is what allows a judgement on an area still thinning, on irritation or on a question of aftercare. The coordinator takes the point to the surgeon at our partner clinic and brings the instruction back to you in English. The adviser stays, for their part, the contact for the hotel, the transfers and the dates. That split keeps questions of density on the medical side and questions of organisation on the side of the stay.

The price gap, which can reach 70% against the UK, is read on the quote once the medical scope is fixed. The pricing there separates Regenera Activa, any transplant and the framework of the stay. Since the quote carries no obligation, putting the project back or changing it stays possible for as long as the dates are not fixed.

The surgeon at our partner clinic decides, file in hand, whether cellular micrografts, a transplant, both in turn or doing nothing make sense in your case. Getting back a density you can read is a medical goal, framed by the examination and by what the literature allows you to expect. Your free quote within 24h puts that decision in writing, along with the English-speaking framework that comes with it: 5-star hotel, VIP transfers and 12 months of follow-up once you are home.

Sources

1. Zari, S. (2021). Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A Retrospective Cohort Study. Clinical, Cosmetic and Investigational Dermatology, 14, 1725-1736.
2. Cruciani, M., Masiello, F., Pati, I., et al. (2023). Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. Blood Transfusion, 21(1), 24-36.
3. ISAPS. (2025). ISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2024. International Society of Aesthetic Plastic Surgery.